Disorders of the Nervous System

Adult Conditional Knockout of PGC-1α Leads to Loss of Dopamine Neurons

Haisong Jiang1,2,3,4, Sung-Ung Kang1,2,3,4, Shuran Zhang, Senthilkumar Karuppagounder1,2,3,4, Jinchong Xu1,2, Yong-Kyu Lee1,2, Bong-Gu Kang1,2, Yunjong Lee1,6,3,4, Jianmin Zhang,1,2 Olga Pletnikova,7 Juan C. Troncoso,2,7 Shelia Pirooznia1,2,3,4, Shaida A. Andrabi,1,2 Valina L. Dawson,1,2,3,4,5,8 and Ted M. Dawson1,2,3,4,5,8

DOI: http://dx.doi.org/10.1523/ENEURO.0183-16.2016

1Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, 2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, 3Adrienne Helis Malvin Medical Research Foundation, New Orleans, Louisiana 70130-2685, 4Diana Helis Henry Medical Research Foundation, New Orleans, Louisiana 70130-2685, 5Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, 6Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, 7Division of Neuropathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and 8Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Visual Abstract

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder. Recent studies have implicated a role for peroxisome proliferator-activated receptor γ coactivator protein-1α (PGC-1α) in PD and in animal or cellular models of PD. The role of PGC-1α in the function and survival of substantia nigra pars compacta (SNpc) dopamine neurons is not clear. Here we find that there are four different PGC-1α isoforms expressed in SH-SY5Y cells, and these four isoforms are expressed across subregions of mouse brain. Adult conditional PGC-1α knock-out mice show a significant loss of dopaminergic neurons that is accompanied by a reduction of dopamine in the striatum. In human PD postmortem tissue from the SNpc, there is a reduction of PGC-1α isoforms and mitochondria mark-

Significance Statement

Recent studies indicate a role for peroxisome proliferator-activated receptor γ coactivator protein-1α (PGC-1α) in maintaining dopaminergic function as well as in promoting survival against toxic environments when overexpressed. It is not yet known whether PGC-1α is required for adult dopaminergic neuronal viability. To address this hypothesis, we investigated dopaminergic neuronal viability in mice following adult conditional knockout of PGC-1α and found that the loss of PGC-1α is sufficient to result in the loss of dopaminergic neurons.
ers. Our findings suggest that all four isoforms of PGC-1α are required for the proper expression of mitochondrial proteins in SNpc DA neurons and that PGC-1α is essential for SNpc DA neuronal survival, possibly through the maintenance of mitochondrial function.

Key words: dopamine neuron; mitochondria; neurodegeneration; PGC-1α; substantia nigra

Introduction

Parkinson’s disease (PD) is the second most common chronic progressive neurodegenerative disorder. As PD progresses, patients experience motor symptoms, including tremor, slowness of movement, stiffness, loss of balance, as well as nonmotor symptoms. The changes in motor function are due to the loss of dopaminergic (DA) neurons. The factors responsible for promoting DA neuronal viability and DA neuronal death are under investigation (Lee et al., 2012; Calabresi et al., 2013). Recently, a role for peroxisome proliferator-activated receptor γ coactivator protein-1α (PGC-1α), a transcriptional coactivator, has been implicated in DA neuronal function and viability. Well studied gene targets for PGC-1α include those involved in energy metabolism, mitochondrial biogenesis, mitochondrial quality control, and mitochondrial function. Through single nucleotide polymorphism analysis, PGC-1α and brain-specific isoforms of PGC-1α have been implicated in neurodegenerative diseases, including amyotrophic lateral sclerosis, Huntington’s disease, and Parkinson’s disease (Soyal et al., 2012; Eschbach et al., 2013). In a genome-wide meta-analysis of gene expression from patients with PD and incipient Lewy body disease, genes regulated by PGC-1α are downregulated (Zheng et al., 2010), and there are PGC-1α polymorphisms that are risk factors for the development of PD (Clark et al., 2011). Additionally, in PD postmortem substantia nigra pars compacta (SNpc), there is epigenetic regulation by promoter-proximal cytosine methylation of the PPARGC1A gene, which encodes PGC-1α and results in the reduced expression of PGC-1α in cell models (Su et al., 2015). In murine primary cortical cultures, genetic deletion of PGC-1α leads to small increases in oligomeric α-synuclein, a key proteinaceous component of Lewy bodies, which is a hallmark feature of PD (Eschbach et al., 2015). In experimental models, PGC-1α overexpression blocks dopaminergic cell loss caused by A53T α-synuclein expression, rotenone intoxication, or parkin deficiency (Ebrahim et al., 2010). The absence of PGC-1α leads to increased susceptibility to the PD neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; St-Pierre et al., 2006). In the setting of parkin gene deletion, the elevation of PARIS, a transcriptional corepressor of PGC-1α, leads to the repression of PGC-1α. Dopaminergic loss observed due to parkin deletion and PARIS expression can be reversed by the overexpression of PGC-1α (Shin et al., 2011). Together, these studies indicate a pivotal role for of PGC-1α in dopaminergic function and a contributory role in DA neuronal viability. However, it is unknown whether PGC-1α is required for adult dopaminergic neuronal viability. To address this possibility, we investigated dopaminergic neuronal viability in mice following adult conditional knockout of PGC-1α. We report that the loss of PGC-1α results in the loss of dopaminergic neurons.

Materials and Methods

Animals

All experimental protocols using animals were approved by the Johns Hopkins Institutional Animal Care and Use Committee. Conditional PGC-1α knock-out mice were purchased from The Jackson Laboratory (https://www.jax.org/strain/009666).

Immunohistochemistry

For immunohistochemistry, animals were perfused with PBS followed by 4% paraformaldehyde. Brains were postfixed with 4% paraformaldehyde and cryoprotected in 30% sucrose. Coronal sections, including striatum and ventral middle brain, were incubated with rabbit polyclonal anti-tyrosine hydroxylase (TH; catalog #NB300-109, Novus Biologicals; RRID: AB_350437). The image was visualized with 3,3’-diaminobenzidine (Sigma-Aldrich) and analyzed by Stereo Investigator software. The sections were incubated with goat polyclonal anti-green fluorescent protein (GFP) (catalog #ab6673, Abcam; RRID: AB_305643), and secondary antibodies were coagulated with Alexa fluorescent for 1 h at room temperature. Brain cell lysates were immunobotted with mouse mono anti-PGC-1α (catalog #ST1202, Millipore; RRID: AB_2237237), rabbit polyclonal anti-succinate dehydrogenase complex,
subunit A (SDHA; catalog #5839S, Cell Signaling Technology; RRID:AB_10707493), mouse anti-Tomm20 (translocase of outer mitochondrial membrane 20; catalog #WH0009804M1, Sigma-Aldrich; RRID:AB_1843992), monoclonal anti-β-actin-peroxidase (Sigma-Aldrich catalog #A3854; RRID:AB_262011).

**HPLC**

Striatal tissue was dissected and sonicated in 0.2 ml of ice-cold 0.01 mM perchloric acid containing 0.01% EDTA and 60 mM 3,4-dihydroxybenzylamine as an internal standard. After centrifugation, 20 μl of the supernatant was injected into a column by using a Prostar-410 autosampler and isocratically eluted through a 4.6 × 150 mm C-18 reverse-phase column. The mobile phase consisted of 90 mM NaH₂PO₄, 1.7 mM octane sulfonic acid, 50 μM, EDTA, and 10% acetonitrile, and the flow rate was kept at 0.9 ml/min. Biogenic amines and their metabolites were detected by a dual-channel Coulchem III electrochemical detector, and the cell potential was set at E1 of −150 mV and E2 of +220 mV, and a guard cell at +350 mV. Data were collected and processed using external standards for respective amines on Clarity data acquisition software. The protein concentrations of tissue homogenates were measured using the BCA Protein Assay kit. Data were normalized to protein concentrations and expressed in nanograms per milligram protein, as previously described normalized to protein concentrations and expressed in nanograms per milligram protein, as previously described normalized to protein concentrations and expressed in nanograms per milligram protein, as previously described normalized to protein concentrations and expressed in nanograms per milligram protein, as previously described normalized to protein concentrations and expressed in nanograms per milligram protein, as previously described.

**Statistical analyses**

All quantitative data are expressed as the mean ± SEM. Statistical significance was determined by Student’s t test. Respective p values are indicated in the figure legends.

**Results**

Since studies suggest that there is significant compensation in the dopaminergic neuronal system when genes are deleted or overexpressed in the germline and thus during development of the dopaminergic system (Dawson et al., 2010; Shin et al., 2011), we chose to conditionally delete PGC-1α. To avoid potential developmental compensation, exons 3–5 of PGC-1α were deleted in 6-week-old PGC-1αΔfloxflox mice (Lucas et al., 2012) by ventral midbrain stereotaxic injection of a GFP-fused Cre recombinase AAV (AAV-Cre-GFP). Ventral midbrain injection of AAV expressing GFP (AAV-GFP) in PGC-1αΔfloxflox mice served as a control (Fig. 1A). Four weeks after injection, effective transduction was assessed by GFP expression, which demonstrates robust colocalization with TH-containing neurons within the substantia nigra (Fig. 1B).

Transduction with AAV-CRE-GFP leads to a 78.0% loss of the PGC-1α isoform and a 59.1% loss of the PGC-1α isoform compared with the control AAV-GFP-injected mice (Lucas et al., 2012) by ventral midbrain stereotaxic injection of a GFP-fused Cre recombinase AAV (AAV-Cre-GFP). Ventral midbrain injection of AAV expressing GFP (AAV-GFP) in PGC-1αΔfloxflox mice served as a control (Fig. 1A). Four weeks after injection, effective transduction was assessed by GFP expression, which demonstrates robust colocalization with TH-containing neurons within the substantia nigra (Fig. 1B). Transduction with AAV-CRE-GFP leads to a 78.0% loss of the PGC-1α isoform and a 59.1% loss of the PGC-1α isoform compared with the control AAV-GFP-injected mice (Fig. 1C,D). Immunoablation also reveals the reduction of two additional isoforms of PGC-1α—a 100 kDa isoform that is reduced by 54.9% and a 160 kDa isoform that is reduced by 91.5% following AAV-CRE-GFP (Fig. 1C,D). The reduction in the 100 and 160 kDa bands following conditional knockout of PGC-1α suggests that the 100 and 160 kDa bands represent unrecognized isoforms of PGC-1α in the brain. Since PGC-1α contributes to the regulation of mitochondrial biogenesis (Scarpulla, 2011), mitochondrial markers for biogenesis were assessed. Accompanying the loss of the PGC-1α isoforms is a 52.5% reduction in mitochondrial protein SDHA and a 58.7% reduction in TOMM20 (Fig. 1C,D). Together, these data show that we achieved a conditional deletion of PGC-1α accompanied by the loss of mitochondrial markers for biogenesis.

Our observations of the reduction in the additional 100 and 160 kDa PGC-1α bands following conditional deletion suggest that there may be unrecognized genomic complexity to PGC-1α than previously thought. The genomic complexity of the protein-coding gene for PGC-1α (Human-GRCh38/hg38; chr4:23,770,000-24,475,000 and Mouse-GRCM38/mm10; chr5:51,450,000-52,120,000) was revealed by cap analysis gene expression (CAGE) dataset from the FANTOM genomics consortium (phases...
1–5) through hubs on the University of California, Santa Cruz (UCSC) Genome Browser (Brett et al., 2002; Forrest et al., 2014). Expressed sequence tags (ESTs) from humans and transcription start site (TSS) activity from mice coupled with the enhancer signal indicate that PGC-1α is structurally dynamic in both humans and mice, and thus that there may be additional isoforms of PGC-1α in addition to those previously investigated (Ruas et al., 2012; Fig. 2A). To determine whether the 100 and 160 kDa bands that we observed are alternate PGC-1α isoforms, we designed PCR primers for two of these alternative isoforms that are conserved between mouse and human to determine whether the message coding for these isoforms exists in mouse brain or mouse heart or the human SH-SY5Y neuroblastoma cell line. Two of these isoforms, which we designate PGC-1α1L and PGC-1α1S corresponding to their transcript size, are detected by RT-PCR (Fig. 2B). PGC-1α1L and PGC-1α4 are also detected in both mouse brain and heart and in SH-SY5Y cells (Fig. 2B). The PGC-1α1L codes for a PGC-1α isoform with a predicted molecular weight of 160 kDa and the PGC-1α1S codes for a PGC-1α isoform with a predicted molecular weight 100 kDa are consistent with our immunoblot results. Corresponding to the reduction of PGC-1α protein in the conditional knockout of PGC-1α, we observed an 83.0% decrease of PGC-1α1L RNA, a 65.1% decrease of PGC-1α1 RNA, a decrease of 48.6% PGC-1α1S RNA, and a 56.7% decrease of PGC-1α4 RNA in the conditional knockout of PGC-1α (Fig. 2C, D). Accompanying the decrease of the RNA of PGC-1α isoforms is a 51.7% reduction in SDHA RNA, and a 43.7% reduction in TOMM20 RNA (Fig. 2C, D).

To determine whether PGC-1α is important in the survival of dopamine neurons, dopaminergic neuronal viability was assessed in the SNpc of adult conditional PGC-1α knock-out mice. Conditional knockout of PGC-1α leads to a 51.7% reduction in tyrosine hydroxylase-positive dopamine neuron and a 51.2% reduction in Nissl-stained neurons 6 months after stereotaxic injection of AAV-Cre-GFP into the ventral midbrain of PGC-1α flox/flox mice compared with the PGC-1α flox/flox mice injected with control AAV-GFP (Fig. 3A, B). Accompanying the loss of dopamine neurons is a 36.6% reduction in dopamine in the striatum, as determined by HPLC (Fig. 3C) and a trend toward a reduction in the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA; Fig. 3D). Since the AAV injection is unilateral, amphetamine-induced rotation was monitored to assess the functional loss of dopamine neurons. The AAV-Cre-
GFP-injected mice exhibit robust ipsilateral turning, while the AAV-GFP-injected mice do not rotate (Fig. 3E).

The levels of PGC-1α isoforms were monitored in human postmortem substantia nigra from PD and control patients (Table 1, Fig. 4). The 160 kDa PGC-1α isoform is reduced by 91.2%. The PGC-1α1 isoform was not detectable in human postmortem tissue. We cannot know whether this lack of detection is due to the specificity of the antibody or to the low abundance of this isoform coupled with the age of the tissue. The PGC-1α4 isoform is reduced by 44.7%. Accompanying these reductions in PGC-1α isoforms is a reduction in the mitochondrial proteins associated with mitochondrial biogenesis by 49.3% in SDHA and a 61.3% reduction in TOMM20 (Fig. 4A,B). Together, these data indicate that there is a reduction in the human condition, in PGC-1α expression that is reflected in the loss of markers associated with mitochondrial biogenesis, suggesting that there is mitochondrial dysfunction in PD substantia nigra.

Discussion

The major finding of this study is the observation that adult conditional knockout of PGC-1α isoforms leads to a loss of dopamine neurons in the substantia nigra. We also identify two brain-enriched isoforms of PGC-1α that we denote PGC-1α1L (160 kDa) and PGC-1α1S (100 kDa). Importantly, these two isoforms are significantly reduced in human postmortem PD substantia nigra. Future studies will be required to understand the regulatory mechanisms of the alternative PGC-1α isoforms identified here.

A potential role for PGC-1α in PD was first suggested by the observation that germline deletion of PGC-1α increased the susceptibility of mice to the neurotoxin MPTP, which is used to selectively produce DA neurotoxicity (St-Pierre et al., 2006). However, the absence of the
degeneration of dopamine neurons in the germline PGC-1α knock-out mice suggested that PGC-1α was not required for the survival of dopamine neurons. Moreover, the overexpression of PGC-1α was shown to impair dopaminergic function and increase the susceptibility of dopamine neurons to MPTP (Ciron et al., 2012; Clark et al., 2012), raising the idea that PGC-1α might be toxic to dopamine neurons. The notion that PGC-1α was not required for the survival of dopamine neurons was challenged by the discovery of parkin interacting substrate (PARIS; Shin et al., 2011). Adult conditional knockout of parkin leads to a progressive loss of dopamine neurons that is dependent upon PARIS repression of PGC-1α (Shin et al., 2011; Siddiqui et al., 2015, 2016; Stevens et al., 2015). PARIS selectively represses PGC-1α in the substantia nigra, leading to the loss of dopamine neurons due to the absence or inactivation of parkin. Consistent with the notion that PGC-1α plays a role in the survival of dopamine neurons due to the absence of parkin, the observation that the overexpression of PGC-1α prevents the loss of dopamine neurons due to the absence of parkin or PARIS overexpression. Thus, the failure to observe the loss of dopamine neurons in the germline deletion of PGC-1α is likely due to developmental compensation. Our observations of the detrimental effect of adult conditional knockout of PGC-1α in dopamine neurons supports the idea that PGC-1α is required for the survival of dopamine neurons (Mudò et al., 2012; Ciron et al., 2015).

The lack of degeneration of dopamine neurons following germline deletion of PGC-1α is likely due to compensatory

### Table 1: Human postmortem tissue used for immunoblot analysis in Figure 4

| Final diagnosis          | Age (years) | Sex | Race | PMD | Tissue |
|-------------------------|-------------|-----|------|-----|--------|
| Control                 | 71          | M   | A    | 24  | SN     |
| Control                 | 71          | M   | W    | 14  | SN     |
| Control                 | 80          | F   | W    | 6   | SN     |
| Control                 | 83          | M   | W    | 21  | SN     |
| PD, PD with dementia    | 76          | M   | W    | 29  | SN     |
| PD                      | 72          | M   | W    | 15  | SN     |
| PD + dementia           | 81          | F   | W    | 13  | SN     |

F, Female; M, male; A, African American; W, white; SN, substantia nigra; PMD, post-mortem delay.

---

**Figure 3.** Gene deletion of PGC-1α leads to the loss of dopamine neurons in the SNpc. A, Representative TH immunohistochemistry and Nissl staining of midbrain sections from SNpc of PGC-1α<sup>fl/o</sup> mice injected with AAV-GFP or AAV-Cr-GFP 6 months after the injection of virus. Scale bar, 100 μm. B, Stereological assessment of TH- and Nissl-positive neurons in the SNpc of PGC-1α<sup>fl/o</sup> mice injected with AAV-GFP or AAV-Cr-GFP (n = 3/group). C, HPLC assessment of the striatal content of dopamine. D, HPLC assessment of the striatal content of dopamine metabolites DOPAC and HVA. E, Amphetamine-induced ipsilateral rotations (n = 3/group). Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.005. Inj, Injected; n.s, not significant.
mechanisms. It is well known that the rodent dopaminergic system possesses strong developmental compensatory mechanisms (Golden et al., 2013). For instance, the deletion of glial cell-derived neurotrophic factor (GDNF) during the critical period of dopamine neuronal development does not lead to the loss of dopamine neurons, whereas adult knockout of GDNF leads to a progressive loss of dopamine neurons (Granholm et al., 2011). In addition, germline deletion of parkin fails to lead to the loss of dopaminergic neurons, whereas adult conditional knockout of parkin leads to a progressive loss of dopamine neurons similar to the adult conditional knockout of PGC-1α (Shin et al., 2011). Moreover, adult deletion of the LIM homeodomain transcription factors Lmx1a and Lmx1b leads to the loss of dopamine neurons (Doucet-Beaupré et al., 2016).

In sporadic PD, genes regulated by PGC-1α are significantly reduced (Zheng et al., 2010; Shin et al., 2011). PGC-1α regulates genes involved in mitochondrial respiration and mitochondrial antioxidant defense, as well as mitochondrial biogenesis (Dabrowska et al., 2015). Here, we observed a significant reduction in the levels of mitochondrial proteins involved in biogenesis, SDHA and TOMM20, suggesting that the reduction in PGC-1α levels leads to a reduction in mitochondrial biogenesis. Similar observations have recently been reported in adult conditional parkin knock-out mice and mice overexpressing PARIS due to the reduction of PGC-1α levels (Stevens et al., 2015). Together, these studies indicate that the maintenance of PGC-1α levels in PD could offer neuroprotective therapeutic opportunities in PD (Zheng et al., 2010; Clark et al., 2011; Shin et al., 2011; Eschbach et al., 2015; Su et al., 2015).

Acknowledgments: We thank Dr. Joohoo Shin for helpful comments. We also thank the Adrienne Helis Malvin Medical Research Foundation and the Diana Helis Henry Medical Research Foundation for their joint participation through their direct engagement in the continuous active conduct of medical research in conjunction with The Johns Hopkins University Hospital and the Johns Hopkins University School of Medicine and the Parkinson’s Disease Program.

Figure 4. Reduction of PGC-1α isoforms, SDHA, and Tomm20 in PD. A, Immunoblots of PGC-1α, SDHA, Tomm20, and β-actin in SN of PD mouse compared with an age-matched control. B, Quantitation of the immunoblots in A normalized to β-actin: Control, n = 4; PD mouse, n = 3. *p < 0.05, **p < 0.005.
References

Brett D, Pospisil H, Valicarcel J, Reich J, Bork P (2002) Alternative splicing and genome complexity. Nat Genet 30:29–30. CrossRef Medline

Calabresi P, Di Filippo M, Gallina A, Wang Y, Stankowski JN, Piccioni B, Dawson VL, Dawson TM (2013) New synaptic and molecular targets for neuroprotection in Parkinson’s disease. Mov Disord 28:51–60. CrossRef Medline

Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL (2012) Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet 21:1861–1876. CrossRef Medline

Ciron C, Zheng L, Bobela W, Knott GW, Leone TC, Kelly DP, Schneider BL (2015) PGC-1alpha activity in nigral dopamine neurons determines vulnerability to α-synuclein. Acta Neuropatol Commun 3:16. CrossRef Medline

Clark J, Reddy S, Zheng K, Betensky RA, Simon DK (2011) Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson’s disease. BMC Med Genet 12:69. CrossRef Medline

Clark J, Silvaggi JM, Kiselak T, Zheng K, Ciolfi EL, Bai Y, Bass CE, Clark J, Reddy S, Zheng K, Betensky RA, Simon DK (2011) Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC Med Genet 12:69. CrossRef Medline

Ciron C, Zheng L, Iwasawa R, Hankir MK, Rahman S, Boobis A, Hajji N (2015) PGC-1alpha controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity. Aging (Albany NY) 7:629–647. CrossRef Medline

Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson’s disease. Neuron 66:646–661. CrossRef Medline

Ducourneau J, Gilbert C, Prodes MF, Chabrat A, Pacelli C, Mugnol N, Rioux V, Charest J, Dang Q, Laguna A, Ericson J, Perlmutter T, Ang SL, Cichetti F, Parent M, Trudeau LE, L'Esquesc M (2016) Lmxa1 and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons. Proc Natl Acad Sci U S A 113:E4387–E4396. CrossRef Medline

Ebrahim AS, Ko LW, Yen SH (2010) Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inductively express alpha-synuclein. Neurosci Lett 473:120–125. CrossRef Medline

Eschbach J, Schwalenstocker B, Soyal SM, Bayer H, Wiesner D, Akimoto C, Nilsön AC, Binsa A, Meyer T, Dupuis L, Danzer KM, Anderson PM, Witting A, Ludolph AC, Patsch W, Weidt P (2013) PGC-1alpha is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet 22:3477–3484. CrossRef Medline

Eschbach J, von Einem B, Muller K, Bayer H, Scheffold A, Morrison BE, Rudolph KL, Thal DR, Witting A, Weidt P, Otto M, Fauler M, Liss B, McLean JP, Spada AR, Ludolph AC, Weishaupt JH, Danzer KM (2015) Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol 77:15–32. CrossRef Medline

Forrest KJR, Kawaji H, Rehli M, Ballem J, de Hoon MJ, Haberle V, von Einem B, Muller K, Bayer H, Wiesner D, Akimoto D, Dawson TM, Dawson VL (2013) Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci 16:1392–1400. CrossRef Medline

Lucas EK, Dougherty SE, McMeekin LJ, Trinh AT, Reid CS, Cowell RM (2012) Developmental alterations in motor coordination and median spiney neuron morphologies in mice lacking pgc-1alpha. PLoS One 7:e42878.

Mudd G, Mikell J, Di Liberto V, Tselykh TV, Olivieri M, Piepenpon P, Eriksson O, Måklia A, Bonomo A, Kairisalo M, Aguirre JA, Korhonen L, Belluardo N, Lindholm D (2012) Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci 69:1153–1165. CrossRef Medline

Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, Greene NP, Wu J, Estall JL, Irving BA, Lanza IR, Raskabah K, Okutsu M, Nair KS, Yan Z, Leinwand LA, Spiegelman BM (2012) A PGC-1α isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell 151:1319–1331. CrossRef Medline

Scarpulla RC (2011) Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 1813:1269–1278. CrossRef Medline

Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconzo JC, Dawson VL, Dawson TM (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell 144:689–702.

Siddiqui A, Bhaumik D, Chinta SJ, Rane A, Rajagopalan S, Lieu CA, Lithgow GJ, Andersen JK (2015) Mitochondrial quality control via the PGC1alpha-1TET signaling pathway is compromised by Parkin P311X mutation but independently restored by rapamycin. J Neurosci 35:12833–12844. CrossRef Medline

Siddiqui A, Rane A, Rajagopalan S, Chinta SJ, Andersen JK (2016) Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson’s disease are attenuated by restoration of PGC1alpha. Neurobiol Dis 93:91–120. CrossRef Medline

Soyal SM, Felder TK, Auer S, Hahne P, Oberkofler H, Witting A, Paulmichl M, Landwehrmeyer GB, Weydt P, Patsch W (2012) A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Hum Mol Genet 21:3461–3473. CrossRef Medline

St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, HANDschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127:397–408. CrossRef Medline

Stevens DA, Lee Y, Kang HC, Lee BD, Lee YI, Bower A, Jiang H, Kang SU, Andrabia SA, Dawson VL, Dawson TM (2015) Parkinson’s disease: vertebrate genetics. Cold Spring Harb Perspect Med. Advance online publication. Retrieved August 19, 2016. doi: 10.1101/cshperspect.a090324. CrossRef Medline

Su X, Chu Y, Kordover JH, Li B, Cao H, Huang L, Nishida M, Song L, Wang D, Fedoroff HJ (2015) PGC-1α promoter methylation in Parkinson’s disease. PLoS One 10:e0134087. CrossRef Medline

Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Ekland AC, Zhang-James Y, Kim PD, Hauser MA, Gründlatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Fedoroff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelveti I, et al. (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2:52ra73.

July/August 2016, 3(4) e0183-16.2016 eNeuro.org